



OFFICE of the DEPUTY PRIME MINISTER
MINISTRY for HEALTH
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

DH Circular 34/2018
DH 3259/2015

26th April 2018

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Methylphenidate 18mg and 36mg Prolonged Release Tablets

It is being brought to your attention that the new stock of methylphenidate 18mg and 36mg prolonged release tablets will change brand from Concerta[®] to Xenidate[®].

Entitlement to Methylphenidate prolonged release tablets will continue to be according to protocol 126, which may be accessed [here](#).

Until all stocks of Concerta[®] are depleted, it is being recommended that the remaining Concerta[®] stocks are dispensed to those patients who take either 18mg or 36mg daily whilst for those patients who are prescribed >36mg daily the Xenidate[®] brand is to be dispensed instead.

For your attention please.

Dr. Denis Vella Baldacchino
Chief Medical Officer